A brief overview on potential prognostic biomarkers in diagnosis of SARS-CoV-2 infection
Mir Naiman Ali, Hajera Tabassum, Roua Alsubki
The world is under pandemic stress due to increased mortality rate owing to the outbreak of novel corona virus termed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 has recently emerged from Wuhan city of China on 31st December 2019. As of 31 August, 2020 a total of 25118689 confirmed cases and 844312 deaths were reported globally indicating urgent necessity to contain the spread of this contagious virus (WHO COVID-19 data). Moreover, patients infected with SARS-COV2 are at risk of adverse complications including cardiovascular diseases - myocardial infarction, liver injury, multiorgan failure and death. In view of the staggering mortality rates reported, it is imperative to diagnose patients with COVID-19 and identify biomarkers that assist in identification of high risk patients. Subsequently, the present review was undertaken to identify prognostic markers associated with morbidity and mortality in COVID-19. Search of the evidences across published meta-analyses or systematic reviews currently investigating on the different types of biomarkers – Blood cell count, inflammatory markers –CRP and cytokines, coagulation markers-D-dimers, cardiac and renal markers associated with COVID severity was accomplished. The outcome of the study provides an insight of the potential prognostic markers that can be adopted as POCT (Point of care testing) in diagnosis of SARS-CoV 2 infection and assist physicians in stratification of the diseased, triage and treatment of patients with COVID-19 disease.